These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 25229459)

  • 1. Association of promoter methylation of RUNX3 gene with the development of esophageal cancer: a meta analysis.
    Wang Y; Qin X; Wu J; Qi B; Tao Y; Wang W; Liu F; Li H; Zhao B
    PLoS One; 2014; 9(9):e107598. PubMed ID: 25229459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological significance and potential drug target of RUNX3 in non-small cell lung cancer: a meta-analysis.
    Xu L; Lan H; Su Y; Li J; Wan J
    Drug Des Devel Ther; 2015; 9():2855-65. PubMed ID: 26082616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alteration in the expression of MGMT and RUNX3 due to non-CpG promoter methylation and their correlation with different risk factors in esophageal cancer patients.
    Saikia S; Rehman AU; Barooah P; Sarmah P; Bhattacharyya M; Deka M; Deka M; Goswami B; Husain SA; Medhi S
    Tumour Biol; 2017 May; 39(5):1010428317701630. PubMed ID: 28468586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk.
    Schulmann K; Sterian A; Berki A; Yin J; Sato F; Xu Y; Olaru A; Wang S; Mori Y; Deacu E; Hamilton J; Kan T; Krasna MJ; Beer DG; Pepe MS; Abraham JM; Feng Z; Schmiegel W; Greenwald BD; Meltzer SJ
    Oncogene; 2005 Jun; 24(25):4138-48. PubMed ID: 15824739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased expression of RUNX3 is correlated with tumor progression and poor prognosis in patients with esophageal squamous cell carcinoma.
    Sugiura H; Ishiguro H; Kuwabara Y; Kimura M; Mitsui A; Mori Y; Ogawa R; Katada T; Harata K; Fujii Y
    Oncol Rep; 2008 Mar; 19(3):713-9. PubMed ID: 18288406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between RUNX3 promoter methylation and gastric cancer: a meta-analysis.
    Fan XY; Hu XL; Han TM; Wang NN; Zhu YM; Hu W; Ma ZH; Zhang CJ; Xu X; Ye ZY; Han CM; Pan WS
    BMC Gastroenterol; 2011 Aug; 11():92. PubMed ID: 21867527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.
    Jiang Y; Tong D; Lou G; Zhang Y; Geng J
    Pathobiology; 2008; 75(4):244-51. PubMed ID: 18580070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association between runt-related transcription factor 3 gene promoter methylation and gastric cancer: A meta-analysis.
    Liu X; Wang L; Guo Y
    J Cancer Res Ther; 2016 Oct; 12(Supplement):50-53. PubMed ID: 27721253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inactivation of RUNX3 predicts poor prognosis in esophageal squamous cell carcinoma after Ivor-Lewis esophagectomy.
    Shi M; Wang Z; Liu XY; Chen D
    Med Oncol; 2014 Dec; 31(12):309. PubMed ID: 25391920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance and association of RUNX3 hypermethylation frequency with colorectal cancer: a meta-analysis.
    Mu WP; Wang J; Niu Q; Shi N; Lian HF
    Onco Targets Ther; 2014; 7():1237-45. PubMed ID: 25053885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the RUNX3 gene methylation in serum DNA from esophagus squamous cell carcinoma, gastric and colorectal adenocarcinoma patients.
    Zheng Y; Zhang Y; Huang X; Chen L
    Hepatogastroenterology; 2011; 58(112):2007-11. PubMed ID: 22234069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological significance and potential drug target of RUNX3 in breast cancer.
    Yu YY; Chen C; Kong FF; Zhang W
    Drug Des Devel Ther; 2014; 8():2423-30. PubMed ID: 25525332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential expression of RUNX genes in human esophageal squamous cell carcinoma: downregulation of RUNX3 worsens patient prognosis.
    Tonomoto Y; Tachibana M; Dhar DK; Onoda T; Hata K; Ohnuma H; Tanaka T; Nagasue N
    Oncology; 2007; 73(5-6):346-56. PubMed ID: 18500170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RUNX3 Promoter Methylation Is Associated with Hepatocellular Carcinoma Risk: A Meta-Analysis.
    Zhang X; He H; Zhang X; Guo W; Wang Y
    Cancer Invest; 2015 Apr; 33(4):121-5. PubMed ID: 25664646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promoter hypermethylation of the RUNX3 gene in esophageal squamous cell carcinoma.
    Long C; Yin B; Lu Q; Zhou X; Hu J; Yang Y; Yu F; Yuan Y
    Cancer Invest; 2007 Dec; 25(8):685-90. PubMed ID: 18058463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RUNX3 is inactivated by promoter hypermethylation in malignant transformation of ovarian endometriosis.
    Guo C; Ren F; Wang D; Li Y; Liu K; Liu S; Chen P
    Oncol Rep; 2014 Dec; 32(6):2580-8. PubMed ID: 25333219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stepwise cumulation of RUNX3 methylation mediated by Helicobacter pylori infection contributes to gastric carcinoma progression.
    Lu XX; Yu JL; Ying LS; Han J; Wang S; Yu QM; Wang XB; Fang XH; Ling ZQ
    Cancer; 2012 Nov; 118(22):5507-17. PubMed ID: 22576578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological significance of RUNX3 gene hypermethylation in hepatocellular carcinoma.
    Yang Y; Ye Z; Zou Z; Xiao G; Luo G; Yang H
    Tumour Biol; 2014 Oct; 35(10):10333-40. PubMed ID: 25037468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
    Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
    Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
    Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
    J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.